Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Dianthus TherapeuticsDNTH | Open-market sale10b5-1 plan | 06/17 | 06/18 | 30,000 sh2 trades | $80.80avg. | $2,423,958.16 | −100.0% | |
Dianthus TherapeuticsDNTH | Open-market sale10b5-1 plan | 06/01 | 06/02 | 26,530 sh3 trades | $90.62avg. | $2,404,076.95 | −86.9% | |
Paula SoteropoulosDirector | Dianthus TherapeuticsDNTH | Open-market sale10b5-1 plan | 05/08 | 05/11 | 599 sh | $85.47 | $51,196.53 | −100.0% |
Ryan SavitzEVP, CFO & Cbo | Dianthus TherapeuticsDNTH | Open-market sale10b5-1 plan | 04/09 | 04/10 | 8,224 sh | $89.84 | $738,844.16 | −100.0% |
Paula SoteropoulosDirector | Dianthus TherapeuticsDNTH | Open-market sale10b5-1 plan | 03/31 | 04/01 | 599 sh | $80.11 | $47,985.89 | −100.0% |
Dianthus TherapeuticsDNTH | Open-market sale10b5-1 plan | 03/31 | 04/01 | 114,367 sh8 trades | $83.00avg. | $9,492,595.5 | −100.0% | |
Paula SoteropoulosDirector | Dianthus TherapeuticsDNTH | Open-market sale10b5-1 plan | 03/24 | 03/26 | 27,594 sh | $78.05 | $2,153,711.7 | −100.0% |
Dianthus TherapeuticsDNTH | Open-market sale10b5-1 plan | 03/12 | 03/13 | 43,682 sh5 trades | $81.49avg. | $3,559,494.57 | −100.0% | |
Dianthus TherapeuticsDNTH | Open-market sale10b5-1 plan | 03/12 | 03/13 | 122,918 sh5 trades | $81.49avg. | $10,016,380.63 | −100.0% | |
Simrat RandhawaEVP, Head of R&D | Dianthus TherapeuticsDNTH | Open-market sale10b5-1 plan | 03/12 | 03/13 | 33,830 sh | $81.48 | $2,756,468.4 | −100.0% |
Ryan SavitzCFO & Cbo | Dianthus TherapeuticsDNTH | Open-market sale10b5-1 plan | 25/12/04 | 25/12/05 | 20,000 sh | $45.18 | $903,600 | −100.0% |
Dianthus TherapeuticsDNTH | Open-market sale10b5-1 plan | 25/11/13–25/11/14 | 25/11/14 | 196,538 sh4 trades | $37.55avg. | $7,379,887.46 | −98.0% | |
Ryan SavitzCFO & Cbo | Dianthus TherapeuticsDNTH | Open-market sale10b5-1 plan | 25/09/09 | 25/09/11 | 20,000 sh | $35.00 | $700,000 | −100.0% |
Peter Evan HarwinDirector | Dianthus TherapeuticsDNTH | Open-market buy | 23/09/29 | 23/10/03 | 24,670 sh | $13.63 | $336,252.1 | +1.3% |
Fairmount Funds ManagementDirector | Dianthus TherapeuticsDNTH | Open-market buy | 23/09/29 | 23/10/03 | 24,670 sh | $13.63 | $336,252.1 | +1.3% |
Tomas KiselakDirector | Dianthus TherapeuticsDNTH | Open-market buy | 23/09/29 | 23/10/03 | 24,670 sh | $13.63 | $336,252.1 | +1.3% |
Peter Evan HarwinDirector | Dianthus TherapeuticsDNTH | Open-market buy | 23/09/26 | 23/09/28 | 30,000 sh | $13.15 | $394,500 | +1.6% |
Fairmount Funds ManagementDirector | Dianthus TherapeuticsDNTH | Open-market buy | 23/09/26 | 23/09/28 | 30,000 sh | $13.15 | $394,500 | +1.6% |
Tomas KiselakDirector | Dianthus TherapeuticsDNTH | Open-market buy | 23/09/26 | 23/09/28 | 30,000 sh | $13.15 | $394,500 | +1.6% |
Dianthus TherapeuticsDNTH | Open-market buy | 23/09/21–23/09/22 | 23/09/25 | 4,000 sh2 trades | $13.20avg. | $52,800 | No record |